Objectives: Emergent treatment of neonatal supraventricular tachycardia (SVT) is very crucial because it may lead to life threating conditions. The aim of this study is to evaluate the neonatal SVTs. Methods: Neonates, who were diagnosed with SVT between December 2014 and May 2018, were analyzed. Clinical findings, electrocardiogram (ECG) and echocardiography findings, 24-hour Holter ECG recordings and medications were evaluated. Results: 46 over 1932 newborns were diagnosed with SVT. 76% of patients were common SVT with narrow QRS and short RP, 13% with Wolff-Parkinson-White syndrome, 4.3% with multifocal atrial tachycardia, 4.3% with atrial flutter, 2.1% with permanent reciprocating junctional tachycardia. Adenosine terminated SVT in 84.4% of the cases. Synchronized cardioversion was performed in 10.8% cases. Amiodarone and/or esmolol for acute treatment was used in 39.1%. Propranolol, digoxin, amiodarone, propafenone and flecainide were the drugs used for monotherapy or combination therapies. Conclusion: In patients with initially unresponsive to standard dose of adenosine and under acute treatment with amiodarone and/or emolol continuous infusion, higher doses of adenosine (300-500 ?g/gr/kg) is very effective. Amiodarone alone and in combination with flecainide seems safe and effective. Keywords: Arrhythmia, neonates, outcome, supraventricular tachycardia, treatment
Corresponding Author: Epcacan S.